Data on two-dose 9-valent HPV vaccinations encouraging, but more needed
Studies of two-dose and three-dose 9-valent human papillomavirus (HPV) vaccines in youth aged 9-14 years and in those up to age 26 found the vaccines to be “generally well tolerated in all vaccination groups,” according to a report at a meeting of the Centers for Disease Control and Prevention’s...
Source: Skin and Allergy News - Category: Dermatology Source Type: news
More News: Allergy | Allergy & Immunology | Cervical Cancer Vaccine | Dermatology | Genital Warts | Human Papillomavirus (HPV) | Skin | Study | Vaccines